Allos Therapeutics announced the presentation of further data from its Phase 2b study of Folotyn (pralatrexate injection) relative to Tarceva (erlotinib, from Genentech) in patients with Stage IIIB/IV ...

FOLOTYN has been available to patients in the U.S. since October 2009. An updated analysis of data from PROPEL, the pivotal study of FOLOTYN in patients with relapsed or refractory PTCL, was published ...

WESTMINSTER, Colo., Sep 25, 2009 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for ...

Spectrum Pharmaceuticals confirmed in a filing that it received notification from the FDA of their early action granting accelerated approval of the company’s New Drug Application for Beleodaq for ...

Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...

“We are committed to making FOLOTYN available in the EU for patients with relapsed or refractory peripheral T-cell lymphoma -- an aggressive and progressive disease where there remains a high unmet ...

Investigator-sponsored preclinical in vivo research showed potential synergy of FOLOTYN® (pralatrexate injection), approved for single therapy of relapsed or refractory peripheral T-cell lymphoma ...

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) and Mundipharma International Corporation Limited (Mundipharma) today jointly announced that the companies have entered ...

HENDERSON, Nev. (AP) — Spectrum Pharmaceuticals Inc. said Monday that the U.S. government extended the patent on its lymphoma drug Folotyn by five years. Spectrum said the patent will now expire on ...

Drug has been shown to improve overall response but not progression-free or overall survival. FDA granted Allos Therapeutics accelerated approval for Folotyn as a single agent for the treatment of ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced ...